View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
ACPS|29 May 2018

Clinical Trial Pharmacovigilance

Pharmacovigilance (PV) in clinical trials is an inherent aspect of good clinical practice (GCP). Although relying on the processes and resources put in place by the sponsor for EudraVigilance reporting, PV of clinical trials requires its own GCP-compliant trial specific provisions. ACPS provides dedicated customised services for the set-up, management and reporting of orderly GCP-compliant PV of early clinical trials in the EU, including initiation and management of data safety monitoring boards.

Pharmacovigilance (PV) for clinical trials (CT) is the duty and responsibility of the sponsor and investigator to ensure a continuous surveillance of the benefit:risk-relationship of the interventional exposure of the trial participants to investigational medicinal products and to inform the competent authorities, ethics committees and investigators of any relevant unfavourable change of this relationship as might become apparent in consequence of the trial.

In the EU, the European Economic Area (EEA) and the EU Member States (MS), PV of investigational medicinal products (IMP) and non-investigational products (NIMP) in CTs irrespective of their regulatory status (authorised or not) is an inherent albeit subordinate aspect of good clinical practice (GCP).  Therefore PV of CTs is subject to the international and national regulations on the orderly conduct of CTs and GCP compliance.

Although relying on the process resources put in place by the sponsor for Eudravigilance reporting, PV of CTs requires its own GCP-compliant trial specific provisions, including risk-based PV-quality management, review of the safety reference information in the investigator brochure, review of the PV-information and instructions in the CT protocol, investigator training and instruction, on-study capture and analysis of safety signals, expert review of serious adverse events (SAE), and expedited handling of SAE and serious unexpected serious adverse reaction (SUSAR) reports.

Relying on more than twenty years of planning, conducting and reporting CTs, ACPS has developed several high-level tools for orderly GCP compliant PV of CTs. Have a look at ACPS‘ PV manual for CTs that is available in the ACPS-Library.

In addition, ACPS provides dedicated customised services for the set-up, management and reporting of orderly GCP compliant PV of your CT in EU.

Based on more than three decades of hands-on experience in early CTs, ACPS has developed dedicated expertise and resources on-trial safety surveillance.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena